Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Mascarenhas on Advancements in the Treatment Landscape of Myelofibrosis

November 28th 2022

John O. Mascarenhas, MD, discusses current advancement in the treatment landscape of myelofibrosis.

Expanding Treatment Options Elevate Outcomes for Patients With Myelofibrosis

November 28th 2022

John Mascarenhas, MD, discusses the shifts from monotherapy to combination therapies in the evolving field of myelofibrosis care.

Dr. Rampal on the Future Research of CDK4/6 Inhibitors in MPNs

November 22nd 2022

Raajit K. Rampal, MD, PhD, discusses the future research of CDK4/6 inhibitors in myeloproliferative neoplasms.

Dr. Rampal on Pelabresib With or Without Ruxolitinib in Myelofibrosis

November 17th 2022

Raajit K. Rampal, MD, PhD, discusses the investigation of pelabresib with or without ruxolitinib in patients with myelofibrosis.

Dr. Schiller on Addressing Unmet Needs in Myelofibrosis Treatment

November 16th 2022

Gary J. Schiller, MD, discusses several areas of unmet need in myelofibrosis, and how to potentially address these challenges.

Innovations Are Poised to Lead MPN/MDS Treatment Landscape in a Positive Direction

November 9th 2022

Ahead of the 40th Annual Chemotherapy Foundation Symposium, Pinkal Desai, MD, addresses the evolving role of targeted therapies in MDS and how clinicians can characterize MDS risk.

Azacitidine-Based Combinations Represent New Treatment Possibilities in MDS

November 2nd 2022

Mikkael A. Sekeres, MD, MS, discussed the changes to the classifications of MDS, the evolution of targeted therapies for patients with acute myeloid leukemia, and approaches for patients with bone marrow failure syndromes.

European Commission Grants Orphan Drug Designation to Selinexor for Myelofibrosis

November 1st 2022

The European Commission has granted an orphan drug designation to selinexor for the treatment of patients with myelofibrosis.

Luspatercept Improves Transfusion Independence in Very Low– to Intermediate-Risk MDS

October 31st 2022

Luspatercept generated a statistically significant improvement in red blood cell transfusion independence with concurrent hemoglobin increase vs epoetin alfa in patients with very low–, low-, or intermediate-risk myelodysplastic syndromes who require RBC transfusions, meeting the primary end point of the phase 3 COMMANDS trial.

Dr. Kuykendall on Treatment Considerations with Ruxolitinib in Myelofibrosis

October 24th 2022

Andrew Kuykendall, MD, discusses treatment considerations with ruxolitinib in myelofibrosis.

Dr. Ali on Key Findings From the Phase 1 Study of Selinexor Plus Ruxolitinib in Myelofibrosis

October 11th 2022

Haris Ali, MD, discusses a phase 1 dose-escalation trial investigating the administration of selinexor in combination with ruxolitinib for patients with treatment-naïve myelofibrosis.

Luspatercept Demonstrates Long-Term Anemia Benefit in Lower-Risk MDS

October 7th 2022

Luspatercept produced favorable safety and long-term efficacy in patients with untreated lower-risk myelodysplastic syndromes, irrespective of subtype.

Novel Interventions May Reduce Phlebotomy Use in Patients With Polycythemia Vera

October 7th 2022

Patients with polycythemia vera, a myeloproliferative neoplasm associated with JAK2 mutations and overproduction of red blood cells, often require regular therapeutic phlebotomies to avoid thrombosis.

Momelotinib Improves OS in Patients With Myelofibrosis and Low Platelet Counts

October 3rd 2022

Momelotinib induced superior 24-week overall survival rates compared with danazol in thrombocytopenic, symptomatic, and anemic patients with myelofibrosis.

Dr. Ali on Ruxolitinib and Navitoclax Combination Therapy in Myelofibrosis

September 30th 2022

Haris Ali, MD, discusses the investigation of ruxolitinib and navitoclax combination therapy in myelofibrosis.

GB2064 Reduces the Level of Bone Marrow Fibrosis in Myelofibrosis

September 30th 2022

Treatment with GB2064 monotherapy for at least 6 months led to a reduction in collagen fibrosis of the bone marrow of at least 1 grade in 4 of 5 evaluable patients with myelofibrosis, according to topline findings from a planned intermediate assessment of the phase 2a MYLOX-1 trial.

Rusfertide Leads to Promising Phlebotomy Reduction in Polycythemia Vera

September 30th 2022

Treatment with rusfertide generated sustained hematocrit control at levels below 45% in patients with polycythemia vera, leading to a reduced need for repeated phlebotomy and eliminating this need in some patients, according to findings from 2 phase 2 clinical trials.

Dr. Kuykendall on Prognostication Factors in Myelofibrosis

September 29th 2022

Andrew Kuykendall, MD, discusses the evolution of prognostication factors in primary and secondary myelofibrosis.

Dr. Mascarenhas on the Investigation of Pelabresib in Myelofibrosis

September 23rd 2022

John O. Mascarenhas, MD, discusses the investigation of pelabresib in myelofibrosis.

FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms

September 19th 2022

Dr Verstovsek discusses the FDA approval of pemigatinib in myeloid/lymphoid neoplasms with FGFR1 rearrangements, the transformative effects of pemigatinib, and the importance of identifying chromosomal abnormalities in patients with this aggressive disease.